Surmodics (NASDAQ:SRDX) Raised to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Surmodics (NASDAQ:SRDX) from a buy rating to a strong-buy rating in a research note issued to investors on Tuesday morning.

Separately, Needham & Company LLC reissued a buy rating and set a $47.00 price target on shares of Surmodics in a research report on Wednesday, April 10th.

Surmodics Trading Down 0.5 %

NASDAQ:SRDX opened at $26.39 on Tuesday. The company has a 50-day moving average price of $29.54 and a 200-day moving average price of $31.88. Surmodics has a 12 month low of $16.79 and a 12 month high of $39.41. The company has a current ratio of 4.84, a quick ratio of 3.97 and a debt-to-equity ratio of 0.24. The stock has a market cap of $375.79 million, a price-to-earnings ratio of 69.45 and a beta of 1.01.

Institutional Trading of Surmodics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its stake in Surmodics by 0.8% during the 1st quarter. BlackRock Inc. now owns 2,284,644 shares of the company’s stock valued at $103,565,000 after purchasing an additional 17,169 shares in the last quarter. Vanguard Group Inc. increased its stake in Surmodics by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 974,726 shares of the company’s stock valued at $29,632,000 after purchasing an additional 15,867 shares in the last quarter. Soleus Capital Management L.P. grew its stake in shares of Surmodics by 0.9% in the fourth quarter. Soleus Capital Management L.P. now owns 775,311 shares of the company’s stock worth $26,454,000 after acquiring an additional 6,833 shares during the period. Renaissance Technologies LLC grew its stake in shares of Surmodics by 8.9% in the first quarter. Renaissance Technologies LLC now owns 633,032 shares of the company’s stock worth $14,420,000 after acquiring an additional 51,794 shares during the period. Finally, State Street Corp grew its stake in shares of Surmodics by 1.1% in the third quarter. State Street Corp now owns 508,352 shares of the company’s stock worth $15,454,000 after acquiring an additional 5,296 shares during the period. 96.63% of the stock is currently owned by institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).